On August 28, 2022, the first “Industry, University Research and Application, Innovative Medicine” Summit Forum ((hereinafter referred to as the “Forum”)) and the inaugural meeting of Tianjin Biomedical Discipline Innovation Consortium (hereinafter referred to as the “Consortium”) were successfully held. Tianjin Beroni Biotechnology Co., Ltd., a subsidiary of Beroni Group, attended the meeting as the Vice Governing Unit of the Consortium and signed the Seed Fund Pool Agreement.
The Consortium is under the guidance of Tianjin Municipal Commission of Education and founded by Tianjin Medical University together with Nankai University, Tianjin University, Tianjin University of Traditional Chinese Medicine, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University General Hospital , the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tasly Pharmaceutical Group Co., Ltd., Tianjin Pharmaceutical Group Co., Ltd., Tianjin Institute of Pharmaceutical Research Co., Ltd., Tianjin Beroni Biotechnology Co., Ltd. and other institutions of higher learning, medical institutions, scientific research institutes and biomedical enterprises to promote win-win cooperation among universities, scientific research institutes, enterprises, medical institutions and the government in Tianjin, promote the integration of the talent, industry, project, technology and capital, further enhance the core competitiveness of Tianjin biomedical industry and promote the high-quality development of the industry.
On the afternoon of August 14, the preparatory meeting kicked off in Tianjin Yanyuan International Hotel. Professor Xiongwen Chen, Ding Ai of Tianjin Medical University and leaders of Tianjin Municipal Commission of Education addressed and announced the establishment of the Consortium, followed by the election of the Governing Unit and Vice Governing Unit. Tianjin Beroni was successfully elected as the Vice Governing Unit.
The participants unanimously adopted the construction plan and the constitution of the Consortium, and discussed its next work plan. After the establishment of the Consortium, all participants will carry out exchanges and cooperation in teaching, scientific research, talent introduction and training, and the integration of industry, university, research, medical, government and enterprises, take talent training, scientific research, team building, platform building, and academic exchanges as the main work contents of the Consortium, to jointly build the brand characteristics of Tianjin biomedical discipline, and enhance the core competitiveness of Tianjin biomedical industry, and promoting high-quality industrial development. At the same time, under the guidance of Tianjin Science and Technology Bureau, the Seed Funding Pool established at the meeting will gradually develop into a provincial and ministerial level to help fund the development of medical research.
The meeting was presided by Professor Kexin Chen, Vice President of Tianjin Medical University Cancer Institute & Hospital, and Professor Wei Zhao, Vice President of College of Pharmacy, Nankai University. Professor Xiongwen Chen, President of College of Pharmacy of Tianjin Medical University and Secretary General of the Consortium, gave a speech to introduce the basic situation of the Consortium to the participants. Yan’an Luo, Deputy Director of Tianjin Municipal Commission of Education, said that the biomedical industry chain is the industrial chain that Tianjin Municipal Committee and Tianjin Municipal Government focuses on developing and the Tianjin Municipal Commission of Education fully supports the Consortium. Yuewei Zhang, Director of the medical department under the leadership of Tianjin Science and Technology Bureau, expressed the great significance of the establishment of the Consortium, which is a great start for the integration of industry and education and the integration of industry, education and research. Academician Xishan Hao, Chairman of the Forum and Honorary Chairman of the Consortium said that the biomedical industry is an important direction of Tianjin’s future industrial development. The establishment of the Consortium will help to enhance the core competitiveness of Tianjin’s biomedical industry, and then drive and promote the coordinated development of Beijing-Tianjin-Hebei biomedical industry.
Academician Xishan Hao, Chairman of the Forum and Honorary Chairman of the Consortium, is now the Director of Tianjin Cancer Center Research Institute and Director of National Clinical Research Center for Cancer. He has made many innovative scientific research achievements in tumor surgery, tumor immunotherapy and tumor epidemiology. Academician Xishan Hao, as a special expert once attended the Third Precision Medicine & Medical Care and Aging International Forum hosted by Beroni Group.
Xiongwen Chen, Secretary General of the Consortium and Professor of Tianjin Medical University is now the dean of College of Pharmacy of Tianjin Medical University. He was a professor of Temple University School of Medicine and a senior member of the American Heart Association. His research direction mainly focuses on the mechanism and possible prevention and treatment measures of cardiovascular disease.
Fengying Yan, Vice President of Tianjin Pharmaceutical Research Institute, Professor Wenbing Yao of China Medical University, Professor Cheng Yang of College of Pharmacy, Nankai University, Professor Ying Yu, Vice President of Tianjin Medical University, Professor Xiubao Ren of Tianjin Medical University Cancer Institute and Hospital, Professor Luyuan Li of Nankai University, Professor Yanchang Lu of Nankai University, Professor Ling Zhang of Tianjin University and other guests made keynote speeches.
At the meeting, the Consortium was announced to establish, and the Governing Unit, Vice Governing Unit and Member units were awarded. The representative of the organizer of the Forum awarded the “Vice Governing Unit” to Tianjin Beroni Biotechnology Co., Ltd.
To promote the industry, university, research and application of the industry, and further promote scientific and technological innovation and transformation of scientific and technological achievements, Tianjin Beroni Biotechnology Co., Ltd. signed the Seed Fund Pool Agreement with the Consortium, aiming to solve the technical problems in the process of enterprise development and strengthen cooperation and exchange with different roles in the biomedical industry chain of Tianjin.
The Forum includes three topics, “Industry, University Research and Application, Innovative Medicine”, “Cardiovascular Doctor Forum” and “Where is the development opportunity of China’s innovative drugs?”. This Forum brought together many experts and scholars from universities, scientific research institutes, hospitals, enterprises for academic reports and exchanges. The participants had a constructive discussion on tumor immunotherapy, cardiovascular disease, digestive system disease, industrial development, etc.
During the parallel session “Where is the development opportunity of Chinese innovative drugs”, the experts shared and discussed the medical strategies of the drug R&D life cycle, the adverse reactions of immunotherapy and the related topics of intestinal micro ecology, and focused on “the next decade of biomedicine” and “how to promote clinical trials efficiently?” to fully discuss. Mr. Jacky Zhang, Executive Chairman was invited to deliver a speech on “how to promote clinical trials efficiently?”, and communicated with the guests on the difficulties in drug research and development, especially in clinical research.
After the Forum, Mr. Jacky Zhang had a more in-depth discussion with the Secretary General of the consortium, Professor Xiongwen Chen of Tianjin Medical University and other participants on the future cooperation and development. He hoped that the member units of the Consortium would cooperate with each other to build a collaborative innovation mechanism, realize complementary advantages, strengthen the construction of teams and platforms, give better play to the advantages of talents, break down the obstacles of systems and mechanisms, and continuously transport talents for medical research, making a contribution to the development of medicine in Tianjin.
Tianjin Beroni also prepared gifts for each guest and set up a booth to help participants better understand the company’s projects to make a foundation for future cooperation. Tianjin Beroni is very honored to be a member of Tianjin Biomedical Discipline Innovation Consortium, and hopes to build a collaborative innovation mechanism with Tianjin universities, medical institutions, scientific research institutes and biomedical enterprises, expand cooperation fields, to achieve talent team construction and discipline development, and make contributions to improving the core competitiveness of Tianjin biomedical industry by relying on own resources.
